NRIX241115C20000
- 5.80
- 0.000.00%
Nurix Therapeutics Newsroom
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 25% Price Boost Is Out Of Tune With Revenues
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $29
Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham
Promising Efficacy and Safety of Nurix Therapeutics' NX-5948 Justifies Buy Rating
Express News | Nurix Therapeutics Announces Presentations at the 66TH American Society of Hematology (Ash) Annual Meeting
Express News | Nurix Therapeutics Inc - to Offer and Sell $300 Million of Common Stock
Express News | Nurix Therapeutics Inc - Enters Amendment No. 2 to Equity Distribution Agreement
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth
Nurix Therapeutics to Participate in Upcoming Investor Conferences
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
UBS Initiates Coverage On Nurix Therapeutics With Buy Rating, Announces Price Target of $35
Barclays Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $31
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
Express News | Nurix Therapeutics Announces Presentations at the 7TH Annual Tpd & Induced Proximity Summit
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $29 to $41
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Ascendis Pharma (ASND)
Nurix Therapeutics Analyst Ratings
Promising Data on Nurix Therapeutics' NX-5948 Supports Buy Rating for Waldenstrom's Macroglobulinemia Treatment
Nurix Therapeutics Presents Positive Results From the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia